Skip to main content


Showing posts from July, 2013

Jobs: Project Manager for Oxford University Chemical Biology Platform

One of our  bff's are the guys and gals at the SGC in Oxford, they have recently got a grant to establish a University-wide Chemical Biology Platform, and are now looking for a Project Manager for this effort. Here are details of the job....

Jobs: diXa Project - Scientific Training & Dissemination Officer (Maternity Cover) at EMBL-EBI

The diXa project is looking to recruit a someone to provide part-time maternity cover for the Scientific Training & Dissemination Officer in the Industry Support team which is based at the European Bioinformatics Institute (EMBL-EBI) located in Hinxton, near Cambridge in the UK. The diXa project is dedicated to developing and implementing a robust and sustainable service infrastructure for data from EU-funded research into non-animal tests for predicting chemical safety ( ). EMBL-EBI is a partner in the diXa project with a number of responsibilities. The overall objectives for the position will be to deliver a core set of project-related training and dissemination services to the Toxicogenomics Research Community and to help foster effective use of resources provided through the project working with colleagues at EMBL-EBI and the other partner sites. The successful candidate will also liaise with other groups involved in training and

New Drug Approvals 2013 - Pt. XI - Afatinib (GilotrifTM)

ATC code : L01XE13 Wikipedia : Afatinib On July 12th 2013 the FDA approved Gilotrif TM (USAN afatinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutation. It is a covalent, irreversible inhibitor of EGFR, ERBB2 and ERBB3. Non small cell lung cancer (NCLS) ( CRUK NCLS ; PDQ NCLS ) accounts for 78% of lung cancer incidences in the UK and is typically resistant to chemotherapy. In clinical studies, afatinib increased the mean Progression Free Survival to 11.1 months from 6.9 months (compared to standard of care Pemetrexed/Cisplatin). Furthermore, response to treatment was observed in tumors harboring several EGFR mutant species although the duration of response varied from 6.9 months to 16.5 months depending on the mutation . Afatinib covalently binds to the kinase domains of EGFR (ErbB1, Uniprot: P00533 ; canSAR: EGFR ”), HER2 (ErbB2, Uniprot: P04626 ;

USAN Watch: July 2013

The USANs for July 2013 have recently been published. USAN Research Code InChIKey (Parent) Drug Class Therapeutic class Target formofilcon B n/a contact lens polymer polymer  n/a futuximab 992DS, Sym004 n/a therapeutic monoclonal antibody EGFR muparfostat , muparfostat sodium PI-88 n/a therapeutic oligosaccharide VEGF, FGF-1, FGF-2 omafilcon B n/a contact lens polymer polymer n/a stenfilcon A n/a contact lens polymer polymer n/a